Susvimo®

100 mg/mL single-dose vial, initial fill needle, refill needle

Ranibizumab binds to the receptor binding site of multiple biologically active forms of VEGF-A, including VEGF 110. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

For intravitreal use via the SUSVIMO ocular implant. The recommended dose is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the implant, with refills every 24 weeks in neovascular AMD and diabetic macular edema, and every 36 weeks in diabetic retinopathy. Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye if clinically necessary. The initial fill, implant insertion and implant removal procedures must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery. Do not administer as a bolus intravitreal injection, and do not substitute other ranibizumab products.